C77-38 Demographic and Clinical Prognostic Factors in Thymoma: A Seer Database Analysis (2000-2021)

Abstract Rationale Thymoma is a rare mediastinal malignancy with a generally favorable prognosis. While prior studies have established the prognostic significance of clinical factors such as disease stage and treatment, a comprehensive analysis of the impact of demographic factors on survival remains a gap in the literature. This study aims to investigate the influence of demographic variables, including age, sex, and marital status, on overall survival in a large, population-based cohort of thymoma patients, alongside established clinical prognostic factors. Methods Patients diagnosed with thymoma between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results (SEER) database using the following ICD-O-3 codes: 8580/3, 8581/3, 8582/3, 8583/3, and 8584/3. Data on patient demographics and survival were extracted. Overall survival was analyzed using Kaplan-Meier curves, with comparisons made via the log-rank test. Hazard ratios (HR) were calculated to quantify risk. All statistical analyses were performed using GraphPad Prism. Results 4,951 patients were included, with 1,713 deaths over a median follow-up of 51 months. Older age predicted poorer survival; patients over 65 years (n = 2,001, 909 deaths) had a median survival of 93 months (95% CI 87-103) compared to 210 months (95% CI 200-230) for patients under 65 (n = 2,941, 795 deaths), with a HR of 2.82 (95% CI 2.54-3.12, P 0.0001). Males (n = 2,449, 921 deaths) showed worse survival (median OS 142 months, 95% CI 133-151) compared to females (n = 2,493, 783 deaths; median OS 157 months, 95% CI 144-168), HR 1.17 (95% CI 1.06-1.28, P = 0.0015). Single patients (n = 2,066, 790 deaths) had significantly poorer survival (median 128 months, 95% CI 114-135) than married patients (n = 2,921, 909 deaths; median 167 months, 95% CI 158-179), HR 1.36 (95% CI 1.23-1.50, P 0.0001). As expected, greater disease spread was strongly associated with worse survival (P 0.0001), with distant (median 77 months), regional (median 151 months), and localized (median 215 months) disease showing progressively better outcomes. Lastly, treatment modality impacted survival (P 0.0001), with no treatment associated with the poorest median survival (51 months), followed by chemotherapy (100 months), radiation (157 months), and surgery (179 months). Conclusions This large, population-based analysis confirms that in addition to established clinical factors such as disease stage and treatment, specific demographic characteristics are independently associated with survival in thymoma. Older age, male sex, and single marital status are significant demographic prognostic factors for worse overall survival. These findings highlight the need to consider sociodemographic variables in patient prognostication and may inform strategies for patient support and follow-up. This abstract is funded by: None